Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887077 | 0.90 | PLG (0.45) | SSTR3CPB2PLGCALCRLITGB1 | |
| SCHEMBL4879319 | 0.89 | F7 (0.43) | KDM1ASSTR3CPB2PLGITGB1 | |
| SCHEMBL4884651 | 0.86 | NTMT1 (0.46) | SSTR3PLGCALCRLITGB1ITGA4 | |
| SCHEMBL4886967 | 0.83 | CHRNB2 (0.47) | PLGCALCRL | |
| SCHEMBL4885609 | 0.82 | CPB2 (0.51) | KDM1ASSTR3CPB2PLG | |
| SCHEMBL4885602 | 0.82 | PLG (0.54) | KDM1ACPB2PLG | |
| SCHEMBL4888152 | 0.79 | MME (0.49) | NPY1R | |
| SCHEMBL4887070 | 0.75 | PLG (0.55) | KDM1ACPB2PLGNPY1R | |
| SCHEMBL11207354 | 0.73 | ALDH1A1 (0.56) | CPB2 | |
| SCHEMBL8853611 | 0.73 | ALDH1A1 (0.56) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | KDM1A 2425/4885SSTR3 3679/4885CPB2 1198/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | KDM1A 2543/4885SSTR3 4637/4885CPB2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.